Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. März 2026 22:45 ET | Quelle: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA)...
02. März 2026 17:00 ET | Quelle: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...
24. Februar 2026 08:45 ET | Quelle: MAIA Biotechnology, Inc.

MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine...
01. Dezember 2025 09:17 ET | Quelle: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted...